Australians discover brain cancer breakthrough

Therapy targeting the cytomegalovirus (CMV) present in many glioblastoma multiforme tumours may significantly prolong life in patients with recurrent disease, say Australian researchers.

In a clinical first, 11 patients with recurrent GBM received multiple infusions of autologous CMV-specific T-cells that had been expanded in vitro.

Overall survival since first recurrence ranged from 133 days to over six years, with a median survival of 58 weeks – results that compared